ReP USP - Resultado da busca

Artigo de periodico
Cardiovascular and renal outcomes with empagliflozin in heart failure (2020)
Packer, Milton; Anker, Stefan D; Butler, Javed; Filippatos, Gerasimos; Pocock, Stuart J; Carson, Peter; Januzzi, James; Verma, Subodh; Tsutsui, Hiroyuki; Bocchi, Edimar Alcides
Source: New england journal of medicine. Unidade: FM
Subjects: ENVELHECIMENTO, DOENÇAS CARDIOVASCULARES, MORTALIDADE, PREVENÇÃO E CONTROLE, INSUFICIÊNCIA CARDÍACA, FISIOPATOLOGIA, INSUFICIÊNCIA RENAL CRÔNICA, HOSPITALIZAÇÃO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PACKER, Milton et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. New england journal of medicine, v. 383, n. 15, p. 1413-1424, 2020Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa2022190. Acesso em: 14 nov. 2024.
APA
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., et al. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. New england journal of medicine, 383( 15), 1413-1424. doi:10.1056/NEJMoa2022190
NLM
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Bocchi EA. Cardiovascular and renal outcomes with empagliflozin in heart failure [Internet]. New england journal of medicine. 2020 ; 383( 15): 1413-1424.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1056/NEJMoa2022190
Vancouver
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Bocchi EA. Cardiovascular and renal outcomes with empagliflozin in heart failure [Internet]. New england journal of medicine. 2020 ; 383( 15): 1413-1424.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1056/NEJMoa2022190
Artigo de periodico
Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial (2019)
Packer, Milton; Butler, Javed; Filippatos, Gerasimos S; Jamal, Waheed; Salsali, Afshin; Schnee, Janet; Kimura, Karen; Zeller, Cordula; George, Jyothis; Bocchi, Edimar Alcides
Source: European journal of heart failure. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, PROTEÍNAS DE TRANSPORTE, MORBIDADE, DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, GLICOSÍDEOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PACKER, Milton et al. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. European journal of heart failure, v. 21, n. 10, p. 1270-1278, 2019Tradução . . Disponível em: https://doi.org/10.1002/ejhf.1536. Acesso em: 14 nov. 2024.
APA
Packer, M., Butler, J., Filippatos, G. S., Jamal, W., Salsali, A., Schnee, J., et al. (2019). Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. European journal of heart failure, 21( 10), 1270-1278. doi:10.1002/ejhf.1536
NLM
Packer M, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Bocchi EA. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial [Internet]. European journal of heart failure. 2019 ; 21( 10): 1270-1278.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1002/ejhf.1536
Vancouver
Packer M, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Bocchi EA. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial [Internet]. European journal of heart failure. 2019 ; 21( 10): 1270-1278.[citado 2024 nov. 14 ] Available from: https://doi.org/10.1002/ejhf.1536
Artigo de periodico
Comparison of omapatrilat and enalapril in patients with chronic heart failure (2002)
Packer, Milton; Califf, Robert M.; Konstam, Marvin A.; Krum, Henry; McMurray, John J.; Rouleau, Jean-Lucien; Swedberg, Karl; Marin-Neto, José Antônio
Source: Circulation. Unidade: FMRP
Assunto: CARDIOPATIAS (TRATAMENTO)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PACKER, Milton et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure. Circulation, v. 103, p. 920-926, 2002Tradução . . Acesso em: 14 nov. 2024.
APA
Packer, M., Califf, R. M., Konstam, M. A., Krum, H., McMurray, J. J., Rouleau, J. -L., et al. (2002). Comparison of omapatrilat and enalapril in patients with chronic heart failure. Circulation, 103, 920-926.
NLM
Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau J-L, Swedberg K, Marin-Neto JA. Comparison of omapatrilat and enalapril in patients with chronic heart failure. Circulation. 2002 ; 103 920-926.[citado 2024 nov. 14 ]
Vancouver
Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau J-L, Swedberg K, Marin-Neto JA. Comparison of omapatrilat and enalapril in patients with chronic heart failure. Circulation. 2002 ; 103 920-926.[citado 2024 nov. 14 ]

USP Schools

ReP

Filtros

Authors

Subjects

Indexado em